Ernexa Therapeutics Inc. (ERNA )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol ERNA
- Company Ernexa Therapeutics Inc.
- Price $6.04
- Changes Percentage 51.38
- Change 2.05
- Day Low $4.57
- Day High $7.7
- Year High $101.25
- Year Low $3.18
- Market Cap $1,897,309
- Price Avg 50 EMA (D) $5.8
- Price Avg 200 EMA (D) $25.65
- Exchange NASDAQ
- Volume 64,067,020
- Average Volume 1,121,224
- Open $5.87
- Previous Close $3.99
- EPS -56
- PE -0.11
- Earnings Announcement 2026-05-20 12:00:00
- Shares Outstanding $314,124
Company brief: ERNEXA THERAPEUTICS INC. (ERNA )
- Healthcare
- Biotechnology
- Mr. Sanjeev Luther
- https://www.brooklynitx.com
- US
- N/A
- 08-29-1991
- US1140822099
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
ERNA Corporation News
Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models
globenewswire.com -- CAMBRIDGE, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease...